Алгоритмы безопасной терапии нестероидными
Алгоритмы безопасной терапии нестероидными. Consilium Medicum. 2008; 10 (7): 148–153.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. An Evidence-Based Approach to Prescribing Nonsteroidal Antiinflammatory Drugs. Third Canadian Consensus Conference. The Journal of Rheumatology 2006; 33: 1.
2. Bareille MP, Montastruc JL, Lapeyre-Mestre M. Liver damage and nonsteroidal anti-inflammatory drugs: case non-case study on the French pharmacovigilance database. Therpaie 2001; 56: 51–5.
3. Bjorkman D. Nonsteroidal anti-inflammatory drug associated toxicity of the liver, lower gastrointestinal tract and the esophagus. Am J Med 1998; 105: 17–21S.
4. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Med 2002; 89 (suppl.): 3D–9.
5. Cochrane Database of Systemic Reviews, 2008; Issue 1.
6. Crofford LJ, Lipsky PE, Brooks P et al. Basic biology and clinical application of specific cycloxygenase-2 inhibitors. Arthritis Pheum 2000; 43: 33 157–33 160.
7. Deny S, Loke YK. Risk of gastrointestinal haemorrage with long term use of aspirin. BMJ 2000; 321: 1183–7.
8. Fitzgerald GA, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. New Engl J Med 2001; 345: 433–42.
9. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 2000; 58 (Suppl. 28): 6–10.
10. Garcia-Rodriguez LA et al. Risk of hospitalisation for upper gastrointestinal tract bleeding associated with Ketorolac, other NSAIDs, calcium antagonists, and other antihypertensive drugd. Arch Intern Med 1998; 158: 33–9.
11. Goldstein JL, Silverstein FE, Agrawal NM et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681–90.
12. Goldstein JL, Silverstein FE, Agrawal NM et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681–90.
13. Greaves RR, Agarwal A, Patch D et al. Inadvertent diclofenac rechallenge from generic and non-generic prescribing, leading to liver transplantation for fulminant liver failure. Eur J Gastroenterol Hepatol 2001; 13: 71–3.
14. http://www.emea.europa.eu/pdfs/human/press/
pr/24732305en.
15. http://www.fda.gov/cder/drug/infopage/cox2/
16. Lanas A et al. Am J Gastroenterol 2005; 100: 1685–93.
17. Maddrey WC, Maurath CJ, Verburg KM et al. The hepatic safety and tolerability of the novel cyclo-oxygenase-2 inhibitor celecoxib. Am J Ther 2000; 7: 153–8.
18. Merlani G, Fox M, Oehen HP et al. Fatal hepatotoxicity secondary to nimesulide. Eur J Clin Pharmacol 2001; 57: 321–6.
19. Pincus T, Swearingen C, Cummins P et al. Preference for nonsteroidal anti-inflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000; 27: 1020–7.
20. Rabinovitz M, Van Thiel DH. Hepatotoxicity of non-steroidal anti-inflammatory drugs. Am J Gastroenterol 1992; 87: 1696–704.
21. Riley TR, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: A case series. Am J Gastroenterol 1998; 93: 1563–5.
22. Rodriguez-Gonzalez FJ, Montero JL, Puente J et al. Orthotopic liver transplantation after subacute liver failure induced by therapeutic doses of ibuprofen. Am J Gastroenterol 2002; 97: 2476–7.
23. Sgro C, Clinard F, Ouazir K et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451–5.
24. Silverstein FE, Faich G, Goldstein JL at al. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis. The CLASS Study: A Randomized Controlled Trial JAMA 2000; 284: 1247–55.
25. Simon LS, Smolen JS, Abramson SB et al Controversies in COX-2 selective inhibition. J Rheumatol 2002; 29: 1501–10.
26. Silverstein FE et al. Ann Intern Med 1998; 123: 241–9.
27. Singh G, Lanes S, Triadafilopoulos G. Am J Med 2004; 100–6.
28. Singh G, Fort J, Goldstein J et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med 2006; 119: 255–66.
29. Singh G, Rosen RD. NSAID-induced gastrointestinal complications: the ARAMIS perspective-1997: Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 51: 8–16.
30. Wongcharatrawee S, Groszmann RJ. Diagnosing portal hypertension. Baillieres Best Pract Res Clin Gastroenterol 2000; 14 (6): 881–94.
2. Bareille MP, Montastruc JL, Lapeyre-Mestre M. Liver damage and nonsteroidal anti-inflammatory drugs: case non-case study on the French pharmacovigilance database. Therpaie 2001; 56: 51–5.
3. Bjorkman D. Nonsteroidal anti-inflammatory drug associated toxicity of the liver, lower gastrointestinal tract and the esophagus. Am J Med 1998; 105: 17–21S.
4. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Med 2002; 89 (suppl.): 3D–9.
5. Cochrane Database of Systemic Reviews, 2008; Issue 1.
6. Crofford LJ, Lipsky PE, Brooks P et al. Basic biology and clinical application of specific cycloxygenase-2 inhibitors. Arthritis Pheum 2000; 43: 33 157–33 160.
7. Deny S, Loke YK. Risk of gastrointestinal haemorrage with long term use of aspirin. BMJ 2000; 321: 1183–7.
8. Fitzgerald GA, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. New Engl J Med 2001; 345: 433–42.
9. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 2000; 58 (Suppl. 28): 6–10.
10. Garcia-Rodriguez LA et al. Risk of hospitalisation for upper gastrointestinal tract bleeding associated with Ketorolac, other NSAIDs, calcium antagonists, and other antihypertensive drugd. Arch Intern Med 1998; 158: 33–9.
11. Goldstein JL, Silverstein FE, Agrawal NM et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681–90.
12. Goldstein JL, Silverstein FE, Agrawal NM et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681–90.
13. Greaves RR, Agarwal A, Patch D et al. Inadvertent diclofenac rechallenge from generic and non-generic prescribing, leading to liver transplantation for fulminant liver failure. Eur J Gastroenterol Hepatol 2001; 13: 71–3.
14. http://www.emea.europa.eu/pdfs/human/press/
pr/24732305en.
15. http://www.fda.gov/cder/drug/infopage/cox2/
16. Lanas A et al. Am J Gastroenterol 2005; 100: 1685–93.
17. Maddrey WC, Maurath CJ, Verburg KM et al. The hepatic safety and tolerability of the novel cyclo-oxygenase-2 inhibitor celecoxib. Am J Ther 2000; 7: 153–8.
18. Merlani G, Fox M, Oehen HP et al. Fatal hepatotoxicity secondary to nimesulide. Eur J Clin Pharmacol 2001; 57: 321–6.
19. Pincus T, Swearingen C, Cummins P et al. Preference for nonsteroidal anti-inflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000; 27: 1020–7.
20. Rabinovitz M, Van Thiel DH. Hepatotoxicity of non-steroidal anti-inflammatory drugs. Am J Gastroenterol 1992; 87: 1696–704.
21. Riley TR, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: A case series. Am J Gastroenterol 1998; 93: 1563–5.
22. Rodriguez-Gonzalez FJ, Montero JL, Puente J et al. Orthotopic liver transplantation after subacute liver failure induced by therapeutic doses of ibuprofen. Am J Gastroenterol 2002; 97: 2476–7.
23. Sgro C, Clinard F, Ouazir K et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451–5.
24. Silverstein FE, Faich G, Goldstein JL at al. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis. The CLASS Study: A Randomized Controlled Trial JAMA 2000; 284: 1247–55.
25. Simon LS, Smolen JS, Abramson SB et al Controversies in COX-2 selective inhibition. J Rheumatol 2002; 29: 1501–10.
26. Silverstein FE et al. Ann Intern Med 1998; 123: 241–9.
27. Singh G, Lanes S, Triadafilopoulos G. Am J Med 2004; 100–6.
28. Singh G, Fort J, Goldstein J et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med 2006; 119: 255–66.
29. Singh G, Rosen RD. NSAID-induced gastrointestinal complications: the ARAMIS perspective-1997: Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 51: 8–16.
30. Wongcharatrawee S, Groszmann RJ. Diagnosing portal hypertension. Baillieres Best Pract Res Clin Gastroenterol 2000; 14 (6): 881–94.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.